- RecruitingPHASE1, PHASE2
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
This study looks at new drug combinations for multiple myeloma that has come back or isn't responding to usual treatment. It checks how safe they are, body reactions, and early signs of how well they might work.
For: Multiple MyelomaUnited States · Canada · Norway - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD)
This study is looking at a new combination of medicines - mezigdomide, carfilzomib, and dexamethasone - for people with multiple myeloma that has come back or isn't responding to other treatments. It wants to see how well this new treatment works.
For: Patients with relapsed/refractory symptomatic multiple myeloma (MM)France - AuthorisedTherapeutic exploratory (Phase II)
A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed multiple myeloma following BCMA-targeting CAR-T cells or bispecific antibodies. The IFM 2024-01 clinical trial (BELAMI)
This study looks at a new combination treatment for multiple myeloma, a type of blood cancer, in people who have already tried other specific treatments. It aims to see how well the new treatment works and if it's safe. It's for adults whose cancer has returned or didn't respond to previous therapies.
For: Relapsed/refractory multiple myelomaFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma
For: Relapsed and refractory multiple myeloma (RRMM)Belgium · Spain